MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
0.6610
-0.0307
-4.44%
Pre Market: 0.6600 -0.001 -0.15% 04:09 04/22 EDT
OPEN
0.6900
PREV CLOSE
0.6917
HIGH
0.7074
LOW
0.6401
VOLUME
190
TURNOVER
0
52 WEEK HIGH
3.080
52 WEEK LOW
0.1986
MARKET CAP
78.90M
P/E (TTM)
-0.2535
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATRA last week (0408-0412)?
Weekly Report · 6d ago
Weekly Report: what happened at ATRA last week (0401-0405)?
Weekly Report · 04/08 09:10
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Grants 3,750 restricted stock units of Atara’s common stock to one newly hired employee. Atara is a leader in T-cell immunotherapy. The company is leveraging its novel allogeneic Epstein-Barr virus (EBV) T- cell platform to develop transformative therapies for patients with cancer and autoimmune diseases.
Barchart · 04/05 15:01
Atara Biotherape: Statement of changes in beneficial ownership of securities
Press release · 04/03 01:05
Atara Biotherapeutics Price Target Cut to $2.30/Share From $4.80 by Stifel
Dow Jones · 04/01 15:06
Atara Biotherapeutics Is Maintained at Hold by Stifel
Dow Jones · 04/01 15:06
Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3
Benzinga · 04/01 14:55
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
TipRanks · 04/01 11:30
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.